VeruSTU:FMW0 28 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates STU:FMW0 with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 939 Biotechnology companies, Veru ranks worse than 106496.17% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Veru's EBITDA for the
three
months ended in Mar. 2026 was €-6.22 Mil. Veru's Revenue for the
three
months ended in Mar. 2026 was €0.00 Mil. Therefore, Veru's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.
Veru (STU:FMW0) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Veru EBITDA Margin % Related Terms
Veru EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Veru's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:FMW0 vs AURX, PDSB, LTRN: EBITDA Margin % Comparison
For the Biotechnology subindustry, Veru's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veru EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Veru's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Veru's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veru (STU:FMW0) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Veru and its competitors. According to the industry distribution chart, Veru ranks #999999 out of 939 companies in the Biotechnology industry.
Is Veru's EBITDA Margin % too high?
Veru's current EBITDA Margin % is 0.00%. Based on the distribution chart, Veru ranks #999999 out of 939 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Veru has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Veru's EBITDA Margin % compare to AURX and PDSB?
According to the Biotechnology industry distribution chart, Veru ranks #999999 out of 939 companies for EBITDA Margin %. This places Veru in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Veru and its competitors. Veru's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veru stock overvalued right now?
Veru (STU:FMW0) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Veru's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Veru (STU:FMW0), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
28GF Score
Get the complete analysis for STU:FMW0
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:FMW0 has been successfully added to your 
